Tan Yong, Li Ping-Ping, Liu Hui, Zhu Jian-Yong, Wu Qing-Song
Department of Hepatobiliary Surgery, Yuebei People's Hospital, Shaoguan, Guangdong, 512026, People's Republic of China.
Department of Ophthalmology, Yuebei People's Hospital, Shaoguan, Guangdong, 512026, People's Republic of China.
J Hepatocell Carcinoma. 2025 Apr 28;12:837-840. doi: 10.2147/JHC.S513695. eCollection 2025.
In Asia, hepatic arterial infusion chemotherapy is an alternative therapeutic option for hepatocellular carcinoma (HCC). However, the current application of HAIC lacks precision, as drug dosages are typically calculated based solely on body surface area. This approach often results in underdosing for patients with larger liver tumors or greater liver volume and overdosing for those with smaller liver tumors or reduced liver volume. Consequently, determining drug dosages according to the specific target volume requiring treatment may enhance individualized and standardized therapy for HCC, aligning with the principles of precision oncology.
在亚洲，肝动脉灌注化疗是肝细胞癌（HCC）的一种替代治疗选择。然而，目前肝动脉灌注化疗的应用缺乏精确性，因为药物剂量通常仅基于体表面积来计算。这种方法常常导致肝肿瘤较大或肝脏体积较大的患者药物剂量不足，而肝肿瘤较小或肝脏体积减小的患者药物剂量过量。因此，根据需要治疗的特定靶体积来确定药物剂量，可能会增强对HCC的个体化和标准化治疗，符合精准肿瘤学的原则。
